Literature DB >> 11496281

Postoperative and amputation-free survival outcomes after femorodistal bypass grafting surgery: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program.

J Feinglass1, W H Pearce, G J Martin, J Gibbs, D Cowper, M Sorensen, S Khuri, J Daley, W G Henderson.   

Abstract

PURPOSE: A noncardiac surgery risk model was used as a means of analyzing variations in postoperative mortality and amputation-free survival for older veterans undergoing femorodistal bypass grafting surgery.
METHODS: A prospective cohort study was undertaken in 105 Veterans Affairs (VA) hospitals at the time of index operation from 1991 to 1995. Each patient was linked to subsequent hospitalizations, major amputation surgery, and survival through 1999. Logistic regression and proportional hazards models were used as a means of developing risk indices on the basis of risk factors from the VA National Surgical Quality Improvement Program. A total of 4288 male veterans 40 years or older underwent artificial, vein, or in situ bypass grafting surgery at the femoral to tibial level. The main outcome measures were 30-day postoperative mortality and amputation-free survival.
RESULTS: Approximately half of all patients had undergone an earlier revascularization or amputation at any level for vascular disease. The 30-day postoperative mortality rate was 2.1% and varied greatly between mortality risk index quartiles (0.6%-5.2%). In a median 44.3 months of follow-up, surviving patients had 17,694 subsequent VA hospitalizations, 1147 patients (26.7%) underwent subsequent major amputation, and 1913 patients (44.6%) died. The overall survival probability was 88% at 1 year and 63% at 5 years; 1- and 5-year (any sided) limb salvage rates were 87% and 74%, respectively, for patients who underwent a femoropopliteal bypass grafting procedure, compared with 77% and 63%, respectively, for patients who underwent a tibial bypass grafting procedure. When amputation and death were combined as end points, amputation-free survival probability rates at 1, 3, and 7.5 years were 74%, 56%, and 29%, respectively. Patients with the best 20% survival risk scores had observed mean survival probability rates 30% higher than patients in the poorest 20% of survival risk.
CONCLUSION: Risk indices derived from the preoperative workup may be of use to clinicians in assessing and communicating risk and prognosis. Risk-adjustment of outcomes is critical for evaluating future disease management initiatives for patients with advanced peripheral arterial disease.

Entities:  

Mesh:

Year:  2001        PMID: 11496281     DOI: 10.1067/mva.2001.116807

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial.

Authors:  Michael S Conte; Dennis F Bandyk; Alexander W Clowes; Gregory L Moneta; Hamid Namini; Lynn Seely
Journal:  J Vasc Surg       Date:  2005-09       Impact factor: 4.268

2.  Popliteo-pedal bypass surgery for critical limb ischemia.

Authors:  D W Good; Hasan Al Chalabi; H Al Chalabi; F Hameed; B Egan; S Tierney; T M Feeley
Journal:  Ir J Med Sci       Date:  2011-07-29       Impact factor: 1.568

Review 3.  Contemporary treatment for critical ischemia: the evidence for interventional radiology or surgery.

Authors:  Keith Hussey; Sivanathan Chandramohan
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

4.  Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia.

Authors:  Shirli Tay; Sami Abdulnabi; Omar Saffaf; Nikolai Harroun; Chao Yang; Clay F Semenkovich; Mohamed A Zayed
Journal:  Clin Diabetes       Date:  2021-10

5.  CEPT1-Mediated Phospholipogenesis Regulates Endothelial Cell Function and Ischemia-Induced Angiogenesis Through PPARα.

Authors:  Mohamed A Zayed; Xiaohua Jin; Chao Yang; Larisa Belaygorod; Connor Engel; Kshitij Desai; Nikolai Harroun; Omar Saffaf; Bruce W Patterson; Fong-Fu Hsu; Clay F Semenkovich
Journal:  Diabetes       Date:  2020-11-19       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.